

Mark R Thursz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6328194/publications.pdf>

Version: 2024-02-01

291
papers

13,409
citations

18482

62
h-index

28297

105
g-index

300
all docs

300
docs citations

300
times ranked

16667
citing authors

#	ARTICLE	IF	CITATIONS
1	Prednisolone or Pentoxifylline for Alcoholic Hepatitis. New England Journal of Medicine, 2015, 372, 1619-1628.	27.0	602
2	EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. Journal of Hepatology, 2018, 69, 154-181.	3.7	591
3	Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe, The, 2020, 1, e245-e253.	7.3	441
4	Association between an MHC Class II Allele and Clearance of Hepatitis B Virus in the Gambia. New England Journal of Medicine, 1995, 332, 1065-1069.	27.0	418
5	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology and Hepatology, 2019, 4, 135-184.	8.1	370
6	Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nature Genetics, 1997, 17, 11-12.	21.4	291
7	Influence of MHC class II genotype on outcome of infection with hepatitis C virus. Lancet, The, 1999, 354, 2119-2124.	13.7	280
8	Requirements for global elimination of hepatitis B: a modelling study. Lancet Infectious Diseases, The, 2016, 16, 1399-1408.	9.1	279
9	The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut, 2016, 65, 1369-1376.	12.1	267
10	Genome-wide meta-analysis of problematic alcohol use in 435,563 individuals yields insights into biology and relationships with other traits. Nature Neuroscience, 2020, 23, 809-818.	14.8	242
11	Source and characterization of hepatic macrophages in acetaminophen-induced acute liver failure in humans. Hepatology, 2012, 56, 735-746.	7.3	232
12	Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet, The, 2019, 393, 1319-1329.	13.7	212
13	Patients With Acute-on-Chronic Liver Failure Have Increased Numbers of Regulatory Immune Cells Expressing the Receptor Tyrosine Kinase MERTK. Gastroenterology, 2015, 148, 603-615.e14.	1.3	207
14	The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations. Seminars in Liver Disease, 2018, 38, 181-192.	3.6	185
15	Micro-elimination “A path to global elimination of hepatitis C. Journal of Hepatology, 2017, 67, 665-666.	3.7	182
16	Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent <i>Clostridioides difficile</i> infection. Gut, 2019, 68, 1791-1800.	12.1	182
17	Blockade of PD1 and TIM3 Restores Innate and Adaptive Immunity in Patients With Acute Alcoholic Hepatitis. Gastroenterology, 2015, 148, 590-602.e10.	1.3	172
18	Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. Aids, 2017, 31, 1621-1632.	2.2	166

#	ARTICLE	IF	CITATIONS
19	Immune-based therapies for hepatocellular carcinoma. <i>Oncogene</i> , 2020, 39, 3620-3637.	5.9	154
20	Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placeboâ€”a Meta-analysis of Individual Data From Controlled Trials. <i>Gastroenterology</i> , 2018, 155, 458-468.e8.	1.3	153
21	Effect of COVID-19 lockdown on alcohol consumption in patients with pre-existing alcohol use disorder. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 886-887.	8.1	153
22	Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. <i>Immunogenetics</i> , 2003, 55, 362-369.	2.4	152
23	MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure. <i>Gut</i> , 2018, 67, 333-347.	12.1	150
24	Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis. <i>Gastroenterology</i> , 2015, 149, 958-970.e12.	1.3	144
25	In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA. <i>Gastroenterology</i> , 2017, 152, 1068-1077.e4.	1.3	141
26	Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. <i>The Lancet Global Health</i> , 2016, 4, e559-e567.	6.3	137
27	Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2010, 53, 542-550.	3.7	134
28	Optimized Sample Handling Strategy for Metabolic Profiling of Human Feces. <i>Analytical Chemistry</i> , 2016, 88, 4661-4668.	6.5	134
29	Inhibiting Growth of <i>Clostridioides difficile</i> by Restoring Valerate, Produced by the Intestinal Microbiota. <i>Gastroenterology</i> , 2018, 155, 1495-1507.e15.	1.3	127
30	Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia. <i>Gut</i> , 2016, 65, 2007-2016.	12.1	125
31	Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. <i>Nature Communications</i> , 2019, 10, 3126.	12.8	124
32	Modulation of monocyte/macrophage function: A therapeutic strategy in the treatment of acute liver failure. <i>Journal of Hepatology</i> , 2014, 61, 439-445.	3.7	115
33	Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. <i>Gut</i> , 2020, 69, 764-780.	12.1	112
34	CD14 ⁺ CD15 ⁺ HLA-DR ⁺ myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure. <i>Gut</i> , 2018, 67, 1155-1167.	12.1	111
35	Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. <i>Future Virology</i> , 2013, 8, 371-380.	1.8	110
36	Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. <i>Hepatology</i> , 2003, 38, 1468-1476.	7.3	109

#	ARTICLE	IF	CITATIONS
37	Genetic susceptibility in chronic viral hepatitis. <i>Antiviral Research</i> , 2001, 52, 113-116.	4.1	99
38	Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 9148-9153.	7.1	99
39	Transmission of hepatitis B virus infection in Gambian families revealed by phylogenetic analysis. <i>Journal of Hepatology</i> , 2001, 35, 99-104.	3.7	94
40	HCV transmission in industrialized countries and resource-constrained areas. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 28-35.	17.8	93
41	Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. <i>The Lancet Global Health</i> , 2016, 4, e568-e578.	6.3	91
42	Understanding the Host Genetics of Chronic Hepatitis B and C. <i>Seminars in Liver Disease</i> , 2011, 31, 115-127.	3.6	85
43	High-Throughput, Machine Learningâ€‘Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2081-2090.e9.	4.4	85
44	<i>Helicobacter pylori</i> Stimulates Dendritic Cells To Induce Interleukin-17 Expression from CD4 ⁺ T Lymphocytes. <i>Infection and Immunity</i> , 2010, 78, 845-853.	2.2	81
45	Validation of Rapid Point-of-Care (POC) Tests for Detection of Hepatitis B Surface Antigen in Field and Laboratory Settings in the Gambia, Western Africa. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1156-1163.	3.9	81
46	Clinical Characteristics and Predictors of Outcomes of Hospitalized Patients With Coronavirus Disease 2019 in a Multiethnic London National Health Service Trust: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e4047-e4057.	5.8	81
47	Secretory leukocyte protease inhibitor: A pivotal mediator of anti-inflammatory responses in acetaminophen-induced acute liver failure. <i>Hepatology</i> , 2014, 59, 1564-1576.	7.3	80
48	Battlefield against hepatitis B infection and HCC in Africa. <i>Journal of Hepatology</i> , 2017, 66, 645-654.	3.7	79
49	Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. <i>European Journal of Gastroenterology and Hepatology</i> , 2000, 12, 667-678.	1.6	76
50	The role of hypercoagulability in liver fibrogenesis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 526-533.	1.5	76
51	Functional microbiomics: Evaluation of gut microbiota-bile acid metabolism interactions in health and disease. <i>Methods</i> , 2018, 149, 49-58.	3.8	76
52	Chronic hepatitis B virus infection in the Asiaâ€‘Pacific region and Africa: Review of disease progression. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 833-843.	2.8	74
53	Parenchymal Extinction: Coagulation and Hepatic Fibrogenesis. <i>Clinics in Liver Disease</i> , 2009, 13, 117-126.	2.1	73
54	Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal scoring system in alcoholic hepatitis. <i>Journal of Hepatology</i> , 2018, 68, 511-518.	3.7	73

#	ARTICLE	IF	CITATIONS
55	The effects of dietary supplementation with inulin and inulinâ€propionate ester on hepatic steatosis in adults with nonâ€alcoholic fatty liver disease. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 372-376.	4.4	73
56	A Polymorphism in IL28B Distinguishes Exposed, Uninfected Individuals From Spontaneous Resolvers of HCV Infection. <i>Gastroenterology</i> , 2011, 141, 320-325.e2.	1.3	72
57	Alcohol-related liver disease: Areas of consensus, unmet needs and opportunities for further study. <i>Journal of Hepatology</i> , 2019, 70, 521-530.	3.7	72
58	Quantifying hepatic steatosis â€“ more than meets the eye. <i>Histopathology</i> , 2012, 60, 971-981.	2.9	68
59	Discovery and validation of urinary metabolites for the diagnosis of hepatocellular carcinoma in West Africans. <i>Hepatology</i> , 2014, 60, 1291-1301.	7.3	67
60	Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. <i>Liver International</i> , 2011, 31, 755-761.	3.9	66
61	Proteomic analysis of extracellular matrix from the hepatic stellate cell line LX-2 identifies CYR61 and Wnt-5a as novel constituents of fibrotic liver. <i>Journal of Proteome Research</i> , 2012, 11, 4052-4064.	3.7	66
62	Fulminant hepatitis associated with hepatitis B virus e antigenâ€negative infection: Importance of host factors. <i>Hepatology</i> , 1995, 22, 1628-1634.	7.3	65
63	Invasive versus non-invasive management of older patients with non-ST elevation myocardial infarction (SENIOR-NSTEMI): a cohort study based on routine clinical data. <i>Lancet, The</i> , 2020, 396, 623-634.	13.7	65
64	Role of monocytes and macrophages in experimental and human acute liver failure. <i>World Journal of Gastroenterology</i> , 2010, 16, 1811.	3.3	64
65	Hepatitis B Virus Core Protein Mutations Are Concentrated in B Cell Epitopes in Progressive Disease and in T Helper Cell Epitopes during Clinical Remission. <i>Journal of Infectious Diseases</i> , 1997, 175, 1093-1100.	4.0	63
66	Association of hepatitis B surface antigen carriage with severe malaria in Gambian children. <i>Nature Medicine</i> , 1995, 1, 374-375.	30.7	62
67	Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. <i>Trials</i> , 2013, 14, 262.	1.6	62
68	Characterization of novel HLA-DR11-restricted HCV epitopes reveals both qualitative and quantitative differences in HCV-specific CD4+ T cell responses in chronically infected and non-viremic patients. <i>European Journal of Immunology</i> , 2001, 31, 1438-1446.	2.9	60
69	Expression of Surfactant Protein D in the Human Gastric Mucosa and during <i>Helicobacter pylori</i> Infection. <i>Infection and Immunity</i> , 2002, 70, 1481-1487.	2.2	57
70	CD8+ T cells from patients with cirrhosis display a phenotype that may contribute to cirrhosis-associated immune dysfunction. <i>EBioMedicine</i> , 2019, 49, 258-268.	6.1	56
71	Variations in <i>Helicobacter pylori</i> Lipopolysaccharide To Evade the Innate Immune Component Surfactant Protein D. <i>Infection and Immunity</i> , 2005, 73, 7677-7686.	2.2	55
72	Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa. <i>Journal of Hepatology</i> , 2018, 69, 776-784.	3.7	55

#	ARTICLE	IF	CITATIONS
73	Hepatitis B virus precore/core variation and interferon therapy. <i>Hepatology</i> , 1995, 22, 1355-1362.	7.3	54
74	Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase. <i>Gut</i> , 2017, 66, 519-529.	12.1	54
75	In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. <i>PLoS ONE</i> , 2020, 15, e0240400.	2.5	54
76	Treatment of Severe Alcoholic Hepatitis. <i>Gastroenterology</i> , 2016, 150, 1823-1834.	1.3	52
77	Homozygosity for rs738409:G in PNPLA3 is associated with increased mortality following an episode of severe alcoholic hepatitis. <i>Journal of Hepatology</i> , 2017, 67, 120-127.	3.7	52
78	A global investment framework for the elimination of hepatitis B. <i>Journal of Hepatology</i> , 2021, 74, 535-549.	3.7	51
79	PD-1 blockade improves Kupffer cell bacterial clearance in acute liver injury. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	51
80	Quantitative versus morphological assessment of liver fibrosis: semi-quantitative scores are more robust than digital image fibrosis area estimation. <i>Liver International</i> , 2003, 23, 28-34.	3.9	49
81	Baseline neutrophil-to-lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 442-453.	3.7	48
82	Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2019, 116, 56-66.	2.8	48
83	The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicity. <i>Liver International</i> , 2015, 35, 764-773.	3.9	46
84	Esophageal Cancer Staging with Endoscopic MR Imaging: Pilot Study. <i>Radiology</i> , 2004, 230, 281-286.	7.3	45
85	Influence of IL10RA and IL22 polymorphisms on outcome of hepatitis C virus infection. <i>Liver International</i> , 2007, 27, 1134-1143.	3.9	45
86	Prednisolone or Pentoxifylline for Alcoholic Hepatitis. <i>New England Journal of Medicine</i> , 2015, 373, 281-283.	27.0	45
87	Anticoagulation in chronic liver disease. <i>Journal of Hepatology</i> , 2017, 66, 1313-1326.	3.7	45
88	Innovative strategies for the elimination of viral hepatitis at a national level: A country case series. <i>Liver International</i> , 2019, 39, 1818-1836.	3.9	44
89	Is antenatal screening for hepatitis C virus cost-effective? A decade's experience at a London centre. <i>Journal of Hepatology</i> , 2015, 63, 797-804.	3.7	42
90	Time matters: Point of care screening and streamlined linkage to care dramatically improves hepatitis C treatment uptake in prisoners in England. <i>International Journal of Drug Policy</i> , 2020, 75, 102608.	3.3	42

#	ARTICLE	IF	CITATIONS
91	Hirmi Valley liver disease: A disease associated with exposure to pyrrolizidine alkaloids and DDT. <i>Journal of Hepatology</i> , 2014, 60, 96-102.	3.7	41
92	Increased Expression of Cytotoxic T-Lymphocyte-Associated Protein 4 by T Cells, Induced by B7 in Sera, Reduces Adaptive Immunity in Patients With Acute Liver Failure. <i>Gastroenterology</i> , 2017, 153, 263-276.e8.	1.3	40
93	Disease Prevention Not Decolonization: A Model for Fecal Microbiota Transplantation in Patients Colonized With Multidrug-resistant Organisms. <i>Clinical Infectious Diseases</i> , 2021, 72, 1444-1447.	5.8	40
94	Mother-to-child transmission of hepatitis B virus in sub-Saharan Africa: time to act. <i>The Lancet Global Health</i> , 2015, 3, e358-e359.	6.3	39
95	Thrombin and factor Xa link the coagulation system with liver fibrosis. <i>BMC Gastroenterology</i> , 2018, 18, 60.	2.0	39
96	In Severe Alcoholic Hepatitis, Serum Keratin-18 Fragments Are Diagnostic, Prognostic, and Theragnostic Biomarkers. <i>American Journal of Gastroenterology</i> , 2020, 115, 1857-1868.	0.4	39
97	Clinical utility of HCV core antigen detection and quantification using serum samples and dried blood spots in people who inject drugs in Dar es Salaam, Tanzania. <i>Journal of the International AIDS Society</i> , 2017, 20, 21856.	3.0	38
98	Character and Temporal Evolution of Apoptosis in Acetaminophen-Induced Acute Liver Failure*. <i>Critical Care Medicine</i> , 2013, 41, 2543-2550.	0.9	37
99	Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment. <i>Hepatology</i> , 2015, 61, 88-97.	7.3	36
100	Rifaximin in non-alcoholic steatohepatitis: An open-label pilot study. <i>Hepatology Research</i> , 2018, 48, 69-77.	3.4	36
101	The Diversity and Management of Chronic Hepatitis B Virus Infections in the United Kingdom: A Wake-up Call. <i>Clinical Infectious Diseases</i> , 2013, 56, 951-960.	5.8	35
102	Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1077-1085.	3.7	35
103	Mutations in Mll2, an H3K4 Methyltransferase, Result in Insulin Resistance and Impaired Glucose Tolerance in Mice. <i>PLoS ONE</i> , 2013, 8, e61870.	2.5	35
104	Hepatitis C, A Global Issue: Access to Care and New Therapeutic and Preventive Approaches in Resource-Constrained Areas. <i>Seminars in Liver Disease</i> , 2014, 34, 089-097.	3.6	34
105	The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. <i>Health Technology Assessment</i> , 2015, 19, 1-104. ^{2.8}		34
106	Genetic Variation in the Interleukin-28B Gene Is Associated with Spontaneous Clearance and Progression of Hepatitis C Virus in Moroccan Patients. <i>PLoS ONE</i> , 2013, 8, e54793.	2.5	33
107	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. <i>Journal of Hepatology</i> , 2022, 76, 275-282.	3.7	33
108	Birth order and risk of hepatocellular carcinoma in chronic carriers of hepatitis B virus: a case-control study in The Gambia. <i>Liver International</i> , 2015, 35, 2318-2326.	3.9	32

#	ARTICLE	IF	CITATIONS
109	Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent <i>Clostridioides difficile</i> infection and beyond: the contribution of gut microbial-derived metabolites. <i>Gut Microbes</i> , 2020, 12, 1810531.	9.8	32
110	Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue. <i>Clinical Science</i> , 2009, 116, 403-413.	4.3	30
111	Systematic review with meta-analysis: high mortality in patients with non-severe alcoholic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 249-257.	3.7	30
112	Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events. <i>Journal of Hepatology</i> , 2021, 75, S36-S48.	3.7	29
113	Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis. <i>Journal of Hepatology</i> , 2021, 75, 177-189.	3.7	29
114	The global burden of chronic hepatitis B virus infection: comparison of country-level prevalence estimates from four research groups. <i>International Journal of Epidemiology</i> , 2021, 50, 560-569.	1.9	29
115	Effect of a thrombin receptor (protease-activated receptor 1, PAR1) gene polymorphism in chronic hepatitis C liver fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1403-1409.	2.8	28
116	Leucocyte ratios are biomarkers of mortality in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 855-865.	3.7	28
117	Global hepatitis C elimination: an investment framework. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 927-939.	8.1	28
118	Intra-familial transmission of hepatitis B virus in Italy: phylogenetic sequence analysis and amino-acid variation of the core gene. <i>Journal of Hepatology</i> , 2002, 36, 248-253.	3.7	26
119	Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. <i>Hepatology</i> , 2017, 66, 1354-1355.	7.3	25
120	Hepatitis B Core-related Antigen: An Alternative to Hepatitis B Virus DNA to Assess Treatment Eligibility in Africa. <i>Clinical Infectious Diseases</i> , 2020, 70, 1442-1452.	5.8	25
121	Prevalence of HBV core promoter/precore/core mutations in Gambian chronic carriers. <i>Journal of Medical Virology</i> , 2001, 65, 664-670.	5.0	24
122	Serum Transferrin Is an Independent Predictor of Mortality in Severe Alcoholic Hepatitis. <i>American Journal of Gastroenterology</i> , 2020, 115, 398-405.	0.4	24
123	Piloting a multidisciplinary clinic for the management of non-alcoholic fatty liver disease: initial 5-year experience. <i>Frontline Gastroenterology</i> , 2013, 4, 263-269.	1.8	23
124	The hepatitis C cascade of care in people who inject drugs in Dar es Salaam, Tanzania. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1438-1445.	2.0	23
125	The diagnostic and prognostic significance of liver histology in alcoholic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 426-431.	3.7	23
126	In-field evaluation of Xpert® HCV viral load Fingerstick assay in people who inject drugs in Tanzania. <i>Liver International</i> , 2020, 40, 514-521.	3.9	22

#	ARTICLE	IF	CITATIONS
127	Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease. <i>Hepatology</i> , 2022, 75, 1026-1037.	7.3	22
128	Host Factors in Chronic Viral Hepatitis. <i>Seminars in Liver Disease</i> , 1997, 17, 345-350.	3.6	21
129	Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C. <i>Aids</i> , 2013, 27, 2485-2488.	2.2	21
130	The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit. <i>Liver International</i> , 2017, 37, 345-353.	3.9	21
131	Prevalent acute-on-chronic liver failure and response to corticosteroids in alcoholic hepatitis. <i>Journal of Hepatology</i> , 2018, 69, 1200-1201.	3.7	21
132	Hepatitis B virus preS2 ¹ 38-55 variants: A newly identified risk factor for hepatocellular carcinoma. <i>JHEP Reports</i> , 2020, 2, 100144.	4.9	21
133	Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: A cohort study. <i>PLoS Medicine</i> , 2022, 19, e1003911.	8.4	21
134	Iron, haemochromatosis and thalassaemia as risk factors for fibrosis in hepatitis C virus infection. <i>Gut</i> , 2007, 56, 613-614.	12.1	20
135	In the shadow of HIV/AIDS: Forgotten diseases in sub-Saharan Africa: Global health issues and funding agency responsibilities. <i>Journal of Public Health Policy</i> , 2012, 33, 430-438.	2.0	20
136	Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV monoinfection independently of the gut microbiome and bacterial translocation. <i>Aids</i> , 2019, 33, 805-814.	2.2	20
137	Forgotten, not neglected: viral hepatitis in resource-limited settings, recall for action. <i>Liver International</i> , 2014, 34, 12-15.	3.9	19
138	Liver transplantation for alcoholic hepatitis: Being consistent about where to set the bar. <i>Liver Transplantation</i> , 2018, 24, 733-734.	2.4	19
139	Pros and cons of genetic association studies in hepatitis B. <i>Hepatology</i> , 2004, 40, 284-286.	7.3	18
140	Global eradication of hepatitis B—feasible or fallacy?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 492-494.	17.8	18
141	Mother-to-child transmission of hepatitis B in sub-Saharan Africa. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 19-20.	9.1	18
142	Intestinal permeability and bacterial translocation in patients with liver disease, focusing on alcoholic aetiology: methods of assessment and therapeutic intervention. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482094261.	3.2	18
143	TLR9 polymorphisms determine murine lymphocyte responses to <i>Helicobacter</i> : Results from a genome-wide scan. <i>European Journal of Immunology</i> , 2007, 37, 1548-1561.	2.9	17
144	Endpoints and patient stratification in clinical trials for alcoholic hepatitis. <i>Journal of Hepatology</i> , 2019, 70, 314-318.	3.7	17

#	ARTICLE	IF	CITATIONS
145	Trace element deficiency is highly prevalent and associated with infection and mortality in patients with alcoholic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 537-544.	3.7	17
146	Diagnostic accuracy of the gamma-glutamyl transpeptidase to platelet ratio (GPR) using transient elastography as a reference. <i>Gut</i> , 2017, 66, 195-196.	12.1	16
147	Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries. <i>BMC Infectious Diseases</i> , 2017, 17, 692.	2.9	16
148	High prevalence and poor linkage to care of transfusion-transmitted infections among blood donors in Dar es Salaam, Tanzania. <i>Journal of Viral Hepatitis</i> , 2019, 26, 750-756.	2.0	16
149	Prognostic significance of troponin level in 3121 patients presenting with atrial fibrillation (The NIHR) Tj ETQq1 1 0.784314 rgBT /Overl e013684.	3.7	16
150	Hepatitis B testing and treatment in HIV patients in The Gambia—Compliance with international guidelines and clinical outcomes. <i>PLoS ONE</i> , 2017, 12, e0179025.	2.5	16
151	Role of surfactant protein D (SP-D) in innate immunity in the gastric mucosa: evidence of interaction with <i>Helicobacter pylori</i> lipopolysaccharide. <i>Journal of Endotoxin Research</i> , 2005, 11, 357-362.	2.5	15
152	Hepatitis B treatment in resource poor settings: time for action. <i>Tropical Medicine and International Health</i> , 2009, 15, 2-4.	2.3	15
153	An overview of hepatitis B prevalence, prevention, and management in the Pacific Islands and Territories. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1854-1866.	2.8	15
154	Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians. <i>Hepatology International</i> , 2015, 9, 251-257.	4.2	14
155	The clinical role of circulating free tumor DNA in gastrointestinal malignancy. <i>Translational Research</i> , 2017, 183, 137-154.	5.0	14
156	Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 684659.	3.9	14
157	Presence of hepcidin-25 in biological fluids: Bile, ascitic and pleural fluids. <i>World Journal of Gastroenterology</i> , 2010, 16, 2129.	3.3	14
158	<i>Helicobacter</i> Infection in the Surfactant Protein D-Deficient Mouse. <i>Helicobacter</i> , 2007, 12, 112-123.	3.5	12
159	Multi-excitation fluorescence spectroscopy for analysis of non-alcoholic fatty liver disease. <i>Lasers in Surgery and Medicine</i> , 2011, 43, 392-400.	2.1	12
160	Intensive Enteral Nutrition in Alcoholic Hepatitis: More Food for Thought. <i>Gastroenterology</i> , 2016, 150, 803-805.	1.3	12
161	Viral hepatitis: is for equitable elimination. <i>Journal of Hepatology</i> , 2018, 69, 762-764.	3.7	12
162	Androgenic anabolic steroid-induced liver injury: two case reports assessed for causality by the updated Roussel Uclaf Causality Assessment Method (RUCAM) score and a comprehensive review of the literature. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000549.	2.7	12

#	ARTICLE	IF	CITATIONS
163	Non-Alcoholic Fatty Liver Disease and Vascular Disease. <i>Current Vascular Pharmacology</i> , 2020, 19, 269-279.	1.7	12
164	Transcutaneous fluorescence spectroscopy as a tool for non-invasive monitoring of gut function: first clinical experiences. <i>Scientific Reports</i> , 2020, 10, 16169.	3.3	11
165	Therapeutic advances in alcohol-associated hepatitis. <i>Journal of Hepatology</i> , 2022, 76, 1279-1290.	3.7	11
166	Detection of Rare Allelic Variants of the Interferon- γ 2 Gene in Human Genomic DNA. <i>Journal of Interferon and Cytokine Research</i> , 1995, 15, 403-406.	1.2	10
167	In vitro ^1H -magnetic resonance spectroscopy of Barrett's esophageal mucosa using magic angle spinning techniques. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 1199-1205.	1.6	10
168	Population-Based Interventions to Reduce the Public Health Burden Related with Hepatitis B Virus Infection in The Gambia, West Africa. <i>Tropical Medicine and Health</i> , 2014, 42, S59-S64.	2.8	10
169	The prevalence and burden of symptoms in patients with chronic liver diseases in The Gambia, West Africa. <i>Palliative Medicine</i> , 2015, 29, 184-185.	3.1	10
170	Breaking Down Barriers to Care in Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2016, 213, 1055-1056.	4.0	10
171	Progress towards elimination of mother-to-child transmission of hepatitis B virus infection in China: a modelling analysis. <i>Bulletin of the World Health Organization</i> , 2021, 99, 10-18.	3.3	10
172	Autoregulatory Role of Interleukin-10 in Hepatitis C Patients Treated with IFN- γ . <i>Journal of Interferon and Cytokine Research</i> , 2004, 24, 585-593.	1.2	9
173	Get Active. <i>Journal of Hepatology</i> , 2012, 56, 5-6.	3.7	9
174	Strategies for Global Elimination of Chronic HBV Infection: 2019 Update. <i>Current Hepatology Reports</i> , 2019, 18, 300-309.	0.9	9
175	Clinical utility of TREAT-B score in African and non-African HBV-infected patients living in Europe. <i>Journal of Hepatology</i> , 2019, 70, 1295-1297.	3.7	9
176	Assessment and Management of Infection in Alcoholic Hepatitis. <i>Seminars in Liver Disease</i> , 2020, 40, 011-019.	3.6	9
177	Genetic Susceptibility in Infectious Diseases. <i>Biotechnology and Genetic Engineering Reviews</i> , 2000, 17, 255-266.	6.2	8
178	Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis. <i>Medical Decision Making</i> , 2020, 40, 830-845.	2.4	8
179	Characteristics and outcomes of clinically diagnosed RT-PCR swab negative COVID-19: a retrospective cohort study. <i>Scientific Reports</i> , 2021, 11, 2455.	3.3	8
180	Serum transferrin as a biomarker of hepatocyte nuclear factor 4 alpha activity and hepatocyte function in liver diseases. <i>BMC Medicine</i> , 2021, 19, 39.	5.5	8

#	ARTICLE	IF	CITATIONS
181	Prevalence and Clinical Significance of Occult Hepatitis B Infection in The Gambia, West Africa. <i>Journal of Infectious Diseases</i> , 2022, 226, 862-870.	4.0	8
182	Can antiviral therapy of chronic hepatitis B prevent the development of hepatocellular carcinoma?. <i>Gut</i> , 2011, 60, 1025-1026.	12.1	7
183	Detection of allele specific differences in IFNL3 (IL28B)mRNA expression. <i>BMC Medical Genetics</i> , 2014, 15, 104.	2.1	7
184	Cost-effectiveness of strategies to improve HCV screening, linkage-to-care and treatment in remand prison settings in England. <i>Liver International</i> , 2020, 40, 2950-2960.	3.9	7
185	NAFLD: Time to apply quantitation in liver biopsies as endpoints in clinical trials. <i>Journal of Hepatology</i> , 2021, 74, 241-242.	3.7	7
186	Acute alcoholic hepatitis and cellular Th1 immune responses to alcohol dehydrogenase. <i>Lancet</i> , The, 2015, 385, S22.	13.7	6
187	Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant. <i>Hepatology</i> , 2018, 68, 1205-1205.	7.3	6
188	ACG Clinical Guideline for Alcoholic Liver Disease: The MELD Threshold for Corticosteroid Treatment has Yet to be Established. <i>American Journal of Gastroenterology</i> , 2019, 114, 175-176.	0.4	6
189	Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania. <i>International Journal of Drug Policy</i> , 2022, 99, 103458.	3.3	6
190	Liver function tests and metabolic-associated fatty liver disease: Changes in upper normal limits, does it really matter?. <i>World Journal of Hepatology</i> , 2021, 13, 2104-2112.	2.0	6
191	The role of different EASL-papers: Clinical practice guidelines vs. position papers vs. conference summaries. <i>Journal of Hepatology</i> , 2010, 53, 221.	3.7	5
192	Blunted increase in serum hepcidin as response to oral iron in HFE-hemochromatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 721-724.	1.6	5
193	Absolute quantitation of disease protein biomarkers in a single LC-MS acquisition using apolipoprotein F as an example. <i>Scientific Reports</i> , 2017, 7, 12072.	3.3	5
194	A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 208-214.	1.6	5
195	The future of therapy for alcoholic hepatitis " Beyond corticosteroids. <i>Journal of Hepatology</i> , 2019, 70, 785-787.	3.7	5
196	Strengthening vaccine confidence during the COVID-19 pandemic: A new opportunity for global hepatitis B virus elimination. <i>Journal of Hepatology</i> , 2020, 73, 490-492.	3.7	5
197	Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China. <i>PLoS ONE</i> , 2021, 16, e0245288.	2.5	5
198	Binge-eating disorder is associated with an unfavorable body mass composition in patients with non-alcoholic fatty liver disease. <i>International Journal of Eating Disorders</i> , 2021, 54, 2025-2030.	4.0	5

#	ARTICLE	IF	CITATIONS
199	Serum keratin 19 (<sc>CYFRA21</sc>â€¹) is a prognostic biomarker in severe alcoholic hepatitis. Liver International, 2022, 42, 1049-1057.	3.9	5
200	NICE Guidelines and a Treatment Algorithm for the Management of Chronic Hepatitis B: A Review of 12 Years Experience in West London. Antiviral Therapy, 2008, 13, 1067-1076.	1.0	5
201	Basis of HBV persistence and new treatment options. Hepatology International, 2014, 8, 486-491.	4.2	4
202	Early diagnosis and treatment: the goal of hepatitis C screening. BMJ, The, 2015, 350, h635-h635.	6.0	4
203	Scaling up HCV treatment in resource-limited countries. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 193-194.	17.8	4
204	Interleukin 28A.rs12980602 and interleukin 28B.rs8103142 genotypes could be protective against HCV infection among Egyptians. Immunologic Research, 2019, 67, 123-133.	2.9	4
205	Genetic variation in HSD17B3 reduces the risk for developing severe alcoholic hepatitis. Journal of Hepatology, 2020, 73, S61-S62.	3.7	4
206	Rapid, non-invasive measurement of gastric emptying rate using transcutaneous fluorescence spectroscopy. Biomedical Optics Express, 2021, 12, 4249.	2.9	4
207	Suppressor CD4⁺T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis. Gut, 2022, 71, 1192-1202.	12.1	4
208	Hepcidin levels in hereditary hyperferritinemia: Insights into the iron-sensing mechanism in hepatocytes. World Journal of Gastroenterology, 2010, 16, 3541.	3.3	4
209	Lipid profiling of preâ€treatment liver biopsy tissue predicts sustained virological response in patients with chronic hepatitis C. Hepatology Research, 2012, 42, 714-720.	3.4	3
210	People who survive an episode of severe alcoholic hepatitis should be advised to maintain total abstinence from alcohol. Hepatology, 2018, 67, 2479-2480.	7.3	3
211	Granulocyte colony-stimulating factor as a novel adjunct to improve hepatitis B vaccination. World Journal of Hepatology, 2010, 2, 136.	2.0	3
212	We need a new approach to clinical trials in alcoholâ€associated hepatitis: Is there a lesson in RECOVERY?. Hepatology, 2022, 76, 909-910.	7.3	3
213	HBV continuum of care using community- and hospital-based screening interventions in Senegal: Results from the PROLIFICA programme. JHEP Reports, 2022, 4, 100533.	4.9	3
214	Could targeting secretory leukocyte protease inhibitor be an effective therapeutic option to prevent infections in acute liver failure?. Immunotherapy, 2014, 6, 667-669.	2.0	2
215	Understanding the Mechanisms of Efficacy of Fecal Microbiota Transplantation in the Treatment of Clostridium Difficile Infection: The Potential Role of Bilemetabolising Enzymes. Gastroenterology, 2017, 152, S47.	1.3	2
216	Reply to: â€œThe PNPLA3 SNP rs738409:G allele is associated with increased liver disease-associated mortality but reduced overall mortality in a population-based cohortâ€ Journal of Hepatology, 2018, 68, 860-862.	3.7	2

#	ARTICLE	IF	CITATIONS
217	META-ANALYSIS OF ALCOHOL DEPENDENCE GWAS DATA FROM EUROPEAN SAMPLES ASCERTAINED FROM CLINIC AND POPULATION BASED APPROACHES. European Neuropsychopharmacology, 2019, 29, S1036.	0.7	2
218	Editorial: importance of an elevated mean platelet volume for prediction of major adverse cardiovascular events in nonalcoholic fatty liver disease – authors’ reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 1093-1094.	3.7	2
219	Clinical utility of quantifying hepatitis B surface antigen in African patients with chronic hepatitis B. Journal of Viral Hepatitis, 2021, 28, 1003-1010.	2.0	2
220	Pathogenesis of Chronic Hepatitis B. , 0, , 308-322.		2
221	Polymorphisms in the IFN-induced GNS PKR, OAS-1, MxA and the outcome of hepatitis C virus infection. Journal of Hepatology, 2002, 36, 18.	3.7	1
222	Genetic diversity in the major histocompatibility complex and the immune response to infectious diseases. , 2003, , 77-116.		1
223	May you live in interesting times. Journal of Hepatology, 2013, 58, 4.	3.7	1
224	Design, method and application of stopping rules in a phase III 2x2 factorial randomised controlled trial. Trials, 2015, 16, .	1.6	1
225	Functional imaging of hepatocellular carcinoma. Hepatic Oncology, 2016, 3, 137-153.	4.2	1
226	Global metabolic changes induced by plant-derived pyrrolizidine alkaloids following a human poisoning outbreak and in a mouse model. Toxicology Research, 2016, 5, 1594-1603.	2.1	1
227	Community-based screening and treatment for chronic hepatitis B in sub-Saharan Africa – Authors' reply. The Lancet Global Health, 2017, 5, e35.	6.3	1
228	Role of expression of the tumour-associated macrophage receptor, MERTK, in hepatocellular carcinoma. Lancet, The, 2017, 389, S72.	13.7	1
229	PS-174-Serum bile acid profiles distinguish severe alcoholic hepatitis from decompensated alcohol-related cirrhosis. Journal of Hepatology, 2019, 70, e108.	3.7	1
230	GS-11-Baseline neutrophil-to-lymphocyte ratio indicates both prevalent and incident infection and acute kidney injury, and is related to corticosteroid Lille response in alcoholic hepatitis. Journal of Hepatology, 2019, 70, e47.	3.7	1
231	THU-460-Longitudinal monitoring of cell-free DNA predicts for transarterial chemo-embolization failure in hepatocellular carcinoma. Journal of Hepatology, 2019, 70, e362.	3.7	1
232	THU-052-Immunometabolic profiling of ascites from patients with acute-on-chronic liver failure reveals increased MerTK+ immunosuppressive myeloid cells and cell death markers with preferential lipid metabolism compared to cirrhosis without organ failure. Journal of Hepatology, 2019, 70, e183.	3.7	1
233	UNEXPECTED INVERTED U-SHAPED RELATIONSHIP BETWEEN TROPONIN LEVEL AND MORTALITY EXPLAINED BY REVASCULARIZATION IN BOTH PATIENTS WITH AND WITHOUT ACUTE CORONARY SYNDROME (TROP-RISK) Tj ETOP 1 0.784314 rgBT	1.0	1
234	1144 FECAL MICROBIOTA TRANSPLANT FOR MULTI-DRUG RESISTANT ORGANISMS: IMPROVED CLINICAL OUTCOMES BEYOND INTESTINAL DECOLONISATION. Gastroenterology, 2020, 158, S-227-S-228.	1.3	1

#	ARTICLE	IF	CITATIONS
235	Validity of the UK early access to medicines scheme criteria for Remdesivir use in patients with COVID-19 disease. <i>Journal of Infection</i> , 2020, 81, 647-679.	3.3	1
236	Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections. <i>Frontline Gastroenterology</i> , 2022, 13, flgastro-2021-101818.	1.8	1
237	Abstract 5269: Discovery and validation of plasma acylcarnitines for the early diagnosis of hepatocellular carcinoma. , 2019, , .		1
238	Optimised systematic review tool: Application to candidate biomarkers for the diagnosis of hepatocellular carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, , .	2.5	1
239	Active inflammation and intestinal metaplasia at the cardia are not related to GORD. <i>Gastroenterology</i> , 2001, 120, A424.	1.3	0
240	Peri Z-line blospy during routine upper GI enddoscopy: From where and how many?. <i>Gastroenterology</i> , 2001, 120, A428.	1.3	0
241	Factor V Leiden Polymorphism and the Rate of Fibrosis Development in Chronic Hepatitis C Virus Infection. <i>Clinical Science</i> , 2002, 103, 41P-41P.	0.0	0
242	Alpha adducin 1 Gly460Trp polymorphism affects the rate of fibrosis development in chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2002, 36, 76.	3.7	0
243	Age at infection, gender and viral genotype affect rate of fibrosis in hepatitis C virus infection. <i>Journal of Hepatology</i> , 2002, 36, 137.	3.7	0
244	Key genetic determinants for the response to Helicobacter infection identified using a genome-wide scan in a mouse model. <i>Gastroenterology</i> , 2003, 124, A402.	1.3	0
245	Columnar lined oesophagus (CLO)- a tissue culture model for basement membrane manipulation. <i>Gastroenterology</i> , 2003, 124, A408-A409.	1.3	0
246	Host surfactant proteins in microbial recognition. , 2010, , 697-713.		0
247	Virological profiles of hepatitis B virus (HBV)-infected African patients treated with tenofovir. <i>International Journal of Infectious Diseases</i> , 2014, 21, 8.	3.3	0
248	P1294 : Proof-of-principle evaluation of immunomodulatory drugs in promoting phagocytosis capacity in patients with liver failure. <i>Journal of Hepatology</i> , 2015, 62, S324.	3.7	0
249	Screening and treatment of hepatitis B virus to prevent liver cancer in Africa. <i>Hepatic Oncology</i> , 2015, 2, 105-109.	4.2	0
250	Reply. <i>Hepatology</i> , 2015, 61, 1438-1438.	7.3	0
251	Effect of prednisolone therapy on monocyte phenotype and function in alcoholic hepatitis. <i>Lancet</i> , The, 2016, 387, S103.	13.7	0
252	Universal screening of acute medical admissions for excess alcohol consumption: Whatâ€™s the misuse?. <i>Journal of Hepatology</i> , 2017, 67, 448-450.	3.7	0

#	ARTICLE	IF	CITATIONS
253	The severity of steatosis does not influence liver stiffness measurements in patients with Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 2017, 66, S586-S587.	3.7	0
254	Reply to: "The long-term prognosis of alcoholic hepatitis is poor and independent of disease severity for patients surviving an acute episode". Journal of Hepatology, 2018, 68, 1332.	3.7	0
255	24 - A Novel Route to Controlling Clostridioides Difficile Growth via Short Chain Fatty Acid and Bile Acid Modulation. Gastroenterology, 2018, 154, S-8.	1.3	0
256	Towards elucidating a universal panel of diagnostic biomarkers for early hepatocellular carcinoma. Journal of Hepatology, 2018, 68, S433.	3.7	0
257	Non invasive assessment of liver fibrosis by three different Shear Wave Techniques: Head-to-Head Performance. Journal of Hepatology, 2018, 68, S643-S644.	3.7	0
258	Bayesian sparse regression modelling more accurately predicts mortality risk than commonly used prognostic scoring systems in patients with severe alcoholic hepatitis. Journal of Hepatology, 2018, 68, S808-S809.	3.7	0
259	Prediction of decompensation events in NASH cirrhosis patients. Journal of Hepatology, 2018, 68, S818-S819.	3.7	0
260	Combination of the Lille model with baseline scores is useful to predict mortality in severe alcoholic hepatitis: a confirmation study in a large database of patients. Journal of Hepatology, 2018, 68, S807.	3.7	0
261	Circulating NK cells in cirrhosis are hypofunctional, with an expanded inhibitory liver-homing CD56dimCD16+/a NK cell population. Journal of Hepatology, 2018, 68, S611.	3.7	0
262	FRI-099-PD-1+ monocytes and macrophages contribute to impaired microbial clearance following acute liver failure. Journal of Hepatology, 2019, 70, e430-e431.	3.7	0
263	PS-025-Elevated tissue homing of monocytes and increased cytotoxic activity of CD8+ T-cells in immune checkpoint inhibitor-induced hepatitis. Journal of Hepatology, 2019, 70, e19-e20.	3.7	0
264	CLINICAL IMPORTANCE OF TROPONIN LEVEL IN 3,121 PATIENTS PRESENTING WITH ATRIAL FIBRILLATION (AF-TROP STUDY). Journal of the American College of Cardiology, 2019, 73, 410.	2.8	0
265	THU-265-In severe alcoholic hepatitis, serum transferrin indicates impaired HNF4a signaling and predicts mortality independently of disease severity. Journal of Hepatology, 2019, 70, e278-e279.	3.7	0
266	THU-306-Liver function tests in NAFLD: Changes in upper normal limits, does it really matter?. Journal of Hepatology, 2019, 70, e295.	3.7	0
267	THU-331-Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease: The importance of an elevated mean platelet volume. Journal of Hepatology, 2019, 70, e305.	3.7	0
268	Letter: role of mean platelet volume levels in the prediction of major acute cardiovascular events in patients with non-alcoholic fatty liver disease" authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 1140-1141.	3.7	0
269	THU-262-A modified Glasgow alcoholic hepatitis score incorporating the neutrophil-to-lymphocyte ratio is superior to other baseline scores of prognosis in alcoholic hepatitis. Journal of Hepatology, 2019, 70, e277-e278.	3.7	0
270	FRI-129-A defect in the Nrf2/HO-1 pathway and Nox2 activation results in regulatory T cell mitochondrial dysfunction in alcohol related cirrhosis. Journal of Hepatology, 2019, 70, e444.	3.7	0

#	ARTICLE	IF	CITATIONS
271	PS-027-The LIT1-CD161 interaction: An important inhibitory interaction for NK cells in cirrhosis. Journal of Hepatology, 2019, 70, e20-e21.	3.7	0
272	SAT-374-Interleukin 35 exerts its suppressive function in chronic liver failure through the induction of an immunosuppressive HLA-G+CD4+ regulatory T -cell population. Journal of Hepatology, 2019, 70, e800.	3.7	0
273	SAT-294-Automated quantitation of steatosis, inflammation, ballooning and fibrosis using machine learning in routine histological images of liver biopsies of patients with NAFLD. Journal of Hepatology, 2019, 70, e767-e768.	3.7	0
274	146â€¦The prognostic implication of a positive troponin across the age spectrum in a quarter of a million patients with suspected acute coronary syndrome (NIHR Health Informatics Collaborative Trop-risk) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		
275	69â€¦The relationship between troponin level and mortality in an unselected population of over 250,000 patients with suspected acute coronary syndrome (NIHR Health Informatics Collaborative Trop-risk) Tj ETQq1 1 0.784314 rgBT /Overlock		
276	OTU-11â€¦Non-severe alcoholic hepatitis is not a benign condition: systematic review and meta-analysis of mortality data. , 2019, , .		0
277	145â€¦The role of high-sensitivity C-reactive protein in predicting mortality beyond troponin in over 100,000 patients with suspected acute coronary syndrome (NIHR Health Informatics Collaborative) Tj ETQq1 1 0.784314 rgBT /Overlock		
278	30â€¦The prognostic implication of troponin level in over 3000 patients presenting with atrial fibrillation (NIHR Health Informatics Collaborative AF-trop Study). , 2019, , .		0
279	57â€¦Invasive versus medical management of elderly patients with non-ST elevation myocardial infarction (NIHR Health Informatics Collaborative Senior-NSTEMI study). , 2019, , .		0
280	P: 81â€¦Previously Identified Candidate Gene Associations in Hepatic Encephalopathy Do Not Replicate in the STOPAH Cohort. American Journal of Gastroenterology, 2019, 114, S39-S39.	0.4	0
281	644 IDENTIFICATION OF NOVEL CHANGES IN MICROBially-DERIVED METABOLITES AFTER FECAL MICROBIOTA TRANSPLANT FOR RECURRENT CLOSTRIDIODES DIFFICILE INFECTION. Gastroenterology, 2020, 158, S-138-S-139.	1.3	0
282	Type III interferon lambda derangements are associated with susceptibility to infection in alcohol-related liver disease. Journal of Hepatology, 2020, 73, S182.	3.7	0
283	Response to Diao et al.. American Journal of Gastroenterology, 2020, 115, 958-958.	0.4	0
284	Response to Sainath et al.. American Journal of Gastroenterology, 2020, 115, 1136-1137.	0.4	0
285	P204â€¦Mitochondrial dysfunction may explain innate immunoparesis and susceptibility to infection of patients with alcoholic hepatitis. , 2021, , .		0
286	Cuts to UK official development assistance budget jeopardise global viral hepatitis elimination goals. The Lancet Gastroenterology and Hepatology, 2021, 6, 527-528.	8.1	0
287	Hepatitis B Virus Infection and Immunity. , 0, , 283-299.		0
288	MP71-15â€¦PREVALENCE OF RECURRENT EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) URINARY TRACT INFECTIONS (UTIS) IN PATIENTS WITHIN A UROLOGY SERVICE. INTRODUCING THE CONCEPT OF FAECAL MICROBIOTA TRANSPLANTATION (FMT) AS A TREATMENT MODALITY. Journal of Urology, 2019, 201, .	0.4	0

#	ARTICLE	IF	CITATIONS
289	Hepatitis B: A Current Global Health Dilemma. Euroasian Journal of Hepato-gastroenterology, 2014, 4, v-vi.	0.5	0
290	Multi-Arm Trial of Inflammatory Signal Inhibitors (MATIS) for Hospitalised Patients with Mild or Moderate COVID-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomised Controlled Trial. Blood, 2021, 138, 4200-4200.	1.4	0
291	Genomic Investigations in Viral Hepatitis: Likely to Help or Hinder?. , 0, , 13-18.		0